Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_2
2
33%
Ph phase_1
4
67%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(2)

Detailed Status

Completed4
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 22 (33.3%)

Trials by Status

completed467%
terminated233%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_2

A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

NCT06113328
completedphase_1

A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)

NCT04924114
terminatedphase_2

Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

NCT06161116
completedphase_1

Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)

NCT05450198
completedphase_1

A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)

NCT06821334
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06113328Phase 2

A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

Terminated
NCT04924114Phase 1

A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)

Completed
NCT06161116Phase 2

Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

Terminated
NCT05450198Phase 1

Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)

Completed
NCT06821334Phase 1

A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)

Completed
NCT06649877Phase 1

MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013)

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6